Benzinga · Sep 29, 2026
B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11
B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
OP
NASDAQ · OPRX
OptimizeRx Corporation
Healthcare · Medical - Healthcare Information Services
$8.55
Down-$0.26 (-2.95%)
Updated Oct 8, 2026, 2:25 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 259.66M
- P/E ratio
- 7,647.53
- Dividend yield
- 0.00%
- 52-week range
- $4.54 – $9.18
- Volume
- 162.12K
- Avg. volume
- 304.06K
Price performance · OPRX
OPRX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
OPRX closed at $8.55 after 21 trading sessions, up 19.25% for the selected period.
- Last close
- $8.55
- Period change
- +19.25%
- Period low
- $7.17
- Period high
- $8.81
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $8.74 | $8.9901 | $8.38 | $8.55 | 162.12K |
| Oct 6, 2026 | $8.82 | $9.18 | $8.79 | $8.81 | 171.94K |
| Oct 5, 2026 | $8.60 | $8.785 | $8.45 | $8.72 | 166.71K |
| Oct 2, 2026 | $8.55 | $8.76 | $8.31 | $8.57 | 224.86K |
| Oct 1, 2026 | $8.42 | $8.86 | $8.295 | $8.39 | 196.47K |
| Sep 30, 2026 | $8.40 | $8.46 | $8.2198 | $8.35 | 204.92K |
| Sep 29, 2026 | $7.92 | $8.37 | $7.821 | $8.36 | 211.69K |
| Sep 28, 2026 | $7.88 | $8.03 | $7.69 | $7.81 | 142.79K |
| Sep 25, 2026 | $7.95 | $8.59 | $7.88 | $8.04 | 487.98K |
| Sep 24, 2026 | $7.51 | $7.91 | $7.345 | $7.89 | 185.19K |
| Sep 23, 2026 | $7.62 | $7.83 | $7.55 | $7.60 | 143.67K |
| Sep 22, 2026 | $7.60 | $7.665 | $7.29 | $7.62 | 121.19K |
| Sep 21, 2026 | $7.31 | $7.63 | $7.13 | $7.56 | 286.27K |
| Sep 18, 2026 | $7.53 | $7.53 | $7.25 | $7.29 | 233.68K |
| Sep 17, 2026 | $7.69 | $7.72 | $7.54 | $7.59 | 72.25K |
| Sep 16, 2026 | $7.62 | $7.68 | $7.495 | $7.53 | 58.34K |
| Sep 15, 2026 | $7.77 | $7.77 | $7.42 | $7.56 | 74.8K |
| Sep 14, 2026 | $7.27 | $7.81 | $7.27 | $7.81 | 96.45K |
| Sep 11, 2026 | $7.24 | $7.32 | $7.06 | $7.29 | 115.23K |
| Sep 10, 2026 | $7.07 | $7.26 | $6.86 | $7.18 | 108.19K |
| Sep 9, 2026 | $7.60 | $7.60 | $7.16 | $7.17 | 78.51K |
Latest OPRX news
The latest Smart Investors Daily articles mentioning OPRX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OPRX research
Overview
Company profile and research snapshot.
Company profile
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | B. Riley Securities | Buy | — |
| Aug 14, 2026 | Citizens | Market Outperform | — |
| May 13, 2026 | Lake Street | Buy | — |
| May 13, 2026 | Stephens & Co. | Equal-Weight | — |
| May 13, 2026 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
Yahoo · Sep 22, 2026
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
The move gives life sciences advertisers a more streamlined way to bring specialized healthcare audiences into their broader digital media strategies.
Yahoo · Sep 22, 2026
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
Expands programmatic access to 800,000 verified prescribers directly in the EHR workflow, making OptimizeRx’s point of care inventory directly available to advertisers using The Trade DeskWALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The T
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
